Pharmalink raises $15m to progress orphans, in-license cancer drugs
This article was originally published in Scrip
Executive Summary
Swedish specialty pharma company Pharmalink has raised SEK196m ($15m) in a series C financing round, which the firm will spend on completing pivotal studies of its lead product Nefecon (PL-56), as well as preparing for pivotal studies of Busulipo (busulfan), and in-licensing and acquisition of cancer products.